JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

JNJ

173.89

+0.19%↑

ABBV

198.28

+0.11%↑

AZN

74.06

+0.64%↑

NVS

118.5

+1.46%↑

ABT

131.52

-2.16%↓

Search

Perrigo Co PLC

Fechado

SetorSaúde

22.02 -2.78

Visão Geral

Variação de preço das ações

24h

Atual

Mín

21.76

Máximo

22.48

Indicadores-chave

By Trading Economics

Rendimento

38M

-6.4M

Vendas

-94M

1B

Rendimento de Dividendos

4.22

Margem de lucro

-0.613

Funcionários

8,379

EBITDA

13M

127M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+39.69% upside

Dividendos

By Dow Jones

Rendimento de Dividendos

Médio do Setor

4.22%

2.54%

Próxima data de dividendos

16 de set. de 2025

Próxima data de ex-dividendo

29 de ago. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

352M

3.7B

Abertura anterior

24.8

Fecho anterior

22.02

Sentimento de Notícias

By Acuity

12%

88%

11 / 374 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Perrigo Co PLC Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

14 de jul. de 2025, 13:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Perrigo to Sell Dermacosmetics Business to KKR With Focus on Streamlining Company

28 de fev. de 2025, 17:42 UTC

Grandes Movimentos do Mercado

Perrigo Shares Jump on FDA's Move to Reclassify Wisconsin Infant-Formula Plant

27 de fev. de 2025, 23:52 UTC

Ganhos

Perrigo Gets Facility Reclassification From FDA as 4Q Profit, Revenue Fall

14 de jul. de 2025, 12:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Perrigo: Business Generated About 5% of 2024 Adjusted Operating Income >PRGO

14 de jul. de 2025, 12:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Perrigo: Dermacosmetics Branded Business Generated About EUR125 Million Sales in 2024 >PRGO

14 de jul. de 2025, 12:32 UTC

Aquisições, Fusões, Aquisições de Empresas

Perrigo: Deal Proceeds to Further Strengthen Balance Sheet >PRGO

14 de jul. de 2025, 12:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Perrigo: Deal Includes EUR300 Million Upfront Cash, Up to EUR27 Million Contingent Payments >PRGO

14 de jul. de 2025, 12:31 UTC

Aquisições, Fusões, Aquisições de Empresas

Perrigo To Sell Dermacosmetics Branded Business to KKR Investment Vehicle >PRGO

14 de jul. de 2025, 12:30 UTC

Aquisições, Fusões, Aquisições de Empresas

Perrigo Announces Agreement to Divest Dermacosmetics Business for Up to EUR327 Million

Comparação entre Pares

Variação de preço

Perrigo Co PLC Previsão

Preço-alvo

By TipRanks

39.69% parte superior

Previsão para 12 meses

Média 31.5 USD  39.69%

Máximo 40 USD

Mínimo 24 USD

Com base em 4 analistas de Wall Street que oferecem metas de preço de 12 meses para Perrigo Co PLC - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

4 ratings

2

Comprar

2

Manter

0

Vender

Pontuação Técnica

By Trading Central

25.22 / 26.85Suporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

11 / 374 Ranking em Saúde

Sentimento de Notícias

Evidência Muito Forte de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Perrigo Co PLC

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.